Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an investigational autologous cell therapy developed by the Mayo Clinic for the treatment of aerodigestive and enterocutaneous fistulae. The active component is the stromal vascular fraction (SVF), a heterogeneous mixture of cells including adipose-derived stem cells, pericytes, endothelial cells, smooth muscle cells, and fibroblasts, isolated from the patient's own adipose tissue via liposuction and enzymatic digestion. The SVF is prepared fresh without cell culture expansion and is applied endoscopically to the fistula site in combination with TISSEEL, a fibrin sealant. The therapy aims to promote tissue healing and closure of fistulae secondary to malignancy, trauma, or surgery, and is currently being evaluated in a Phase 1 pilot study (NCT03792360).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous adipose-derived stromal vascular fraction (Mayo Clinic).